alisertib (Aurora A kinase inhibitor MLN8237)
Jump to navigation
Jump to search
Indications
- investigative agent for treatment of
Mechanism of action
More general terms
References
- ↑ Wikipedia: Alisertib https://en.wikipedia.org/wiki/Alisertib
- ↑ PubChem: 24771867
- ↑ https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alisertib
- ↑ 4.0 4.1 Kelly et al. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma Clin Cancer Res; 24(24) December 15, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30082475 <Internet> http://clincancerres.aacrjournals.org/content/24/24/6150.full-text.pdf
- ↑ 5.0 5.1 Friedberg, JW et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. Journal of Clinical Oncology. 32 (1): 44-50. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24043741
- ↑ 6.0 6.1 Melichar B, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet Oncoloby VOLUME 16, ISSUE 4, P395-405, APRIL 01, 2015 https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(15)70051-3.pdf
- ↑ 7.0 7.1 https://www.centerwatch.com/clinical-trials/listings/196186/mucinous-adenocarcinoma-of-the-colon-irinotecan-alisertib-treating-patients/?